- Home
- PCTY vs BMRN Comparison
PCTY vs BMRN Comparison
Compare PCTY & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCTY
- BMRN
- Stock Information
- Founded
- PCTY 1997
- BMRN 1996
- Country
- PCTY United States
- BMRN United States
- Employees
- PCTY N/A
- BMRN N/A
- Industry
- PCTY Computer Software: Prepackaged Software
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- PCTY Technology
- BMRN Health Care
- Exchange
- PCTY Nasdaq
- BMRN Nasdaq
- Market Cap
- PCTY 9.9B
- BMRN 10.0B
- IPO Year
- PCTY 2014
- BMRN 1999
- Fundamental
- Price
- PCTY $150.38
- BMRN $53.24
- Analyst Decision
- PCTY Buy
- BMRN Buy
- Analyst Count
- PCTY 17
- BMRN 18
- Target Price
- PCTY $223.25
- BMRN $93.71
- AVG Volume (30 Days)
- PCTY 603.0K
- BMRN 2.1M
- Earning Date
- PCTY 11-04-2025
- BMRN 10-24-2025
- Dividend Yield
- PCTY N/A
- BMRN N/A
- EPS Growth
- PCTY 10.74
- BMRN 154.69
- EPS
- PCTY 4.02
- BMRN 3.40
- Revenue
- PCTY $1,595,221,000.00
- BMRN $3,063,608,000.00
- Revenue This Year
- PCTY $9.77
- BMRN $13.35
- Revenue Next Year
- PCTY $8.97
- BMRN $9.18
- P/E Ratio
- PCTY $37.39
- BMRN $15.68
- Revenue Growth
- PCTY 13.74
- BMRN 18.36
- 52 Week Low
- PCTY $147.60
- BMRN $51.57
- 52 Week High
- PCTY $223.80
- BMRN $73.51
- Technical
- Relative Strength Index (RSI)
- PCTY 32.38
- BMRN 43.72
- Support Level
- PCTY $147.60
- BMRN $51.57
- Resistance Level
- PCTY $157.45
- BMRN $53.94
- Average True Range (ATR)
- PCTY 3.64
- BMRN 1.34
- MACD
- PCTY -0.07
- BMRN -0.04
- Stochastic Oscillator
- PCTY 18.83
- BMRN 35.57
About PCTY Paylocity Holding Corporation
Founded in 1997, Paylocity is a cloud-based human capital management and payroll platform servicing midmarket customers. The company's average client size is around 150 employees. Its products help with recruiting and onboarding, payroll, time and labor, human resources, benefits, learning, and performance and compensation workflows. In fiscal 2025, the company generated over $1.5 billion in revenue across more than 41,000 customers.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.